Estrogens used for replacement therapy in postmenopausal women

Gynecological Endocrinology

Volumn 15, Issue SUPPL. 4, 2001, Pages 17-25

  Stanczyk, F Z ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b WOMEN S AND CHILDREN S HOSPITAL   (United States)

Author keywords

Estrogens; Pharmacokinetics; Potency

Indexed keywords

EID: 0141770573     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Stanczyk FZ. Structure-function relationships and metabolism of estrogens and progestogens. In Fraser IS, Jansen RPS, Lobo RA, Whitehead MI, eds. Estrogens and Progestogens in Clinical Practice. London: Churchill Livingstone, 1998:39
2. Stanczyk FZ. Estrogens: different types and properties. In Lobo RA, Kelsey J, Marcus R, eds. Menopause Biology and Pathobiology. San Diego: Academic Press, 2000:421-8
3. Marker RE, Rohrmann E. The structure of the side chain of sarsaspogenin. J Am Chem Soc 1939; 61:846-51
4. Marker RE, Tsuakamoto T, Turner DL. Diosgenin. J Am Chem Soc 1940;62:2525-32
5. Edwards JA, Henzl MR. Chemical synthesis. In Fraser IS, Jansen RPS, Lobo RA, Whitehead MI, eds. Estrogens and Progestogens in Clinical Practice. London: Churchill Livingstone, 1998:55-70
6. USP XXII, 1990; Supplement 7 (November, 1992) and Supplement 8 (May, 1993)
7. FDA Docket No. 94P-0429/CP
8. Bhavnani BR. The saga of the ring B unsaturated equine estrogens. Endocr Rev 1988;9:396-416
9. Bhavnani BR. Pharmacokinetics and pharmacodynamics of conjugated equine estrogens: chemistry and metabolism. Proc Soc Exp Biol Med 1998;217:6-16
10. Bhavnani BR, Woolover CA. Interaction of ring B unsaturated estrogens with estrogen receptors of human endometrium and rat uterus. Steroids 1991;56:201-9
11. Bhavnani BR, Cecutti A, Dey MS. Effects on postmenopausal women of delta-8-estrone sulfate: a novel estrogen component of Premarin. J Soc Gynecol Invest 1997;4(Suppl):177A, abstr 392
12. Barnes RB, Levrant SG. Pharmacology of estrogens. In Lobo RA, ed. Treatment of the Postmenopausal Woman. Philadelphia: Lippincott, Williams & Wilkins, 1999:95-104
13. Slater CC, Hodis HN, Mack WJ, Shoupe D, Paulson RJ, Stanczyk FZ. Markedly elevated levels of estrone sulfate folio wing long-term oral but not transdermal administration of estradiol in postmenopausal women. Menopause 2001;in press
14. Stanczyk FZ, Patel S, Hodis HN, et al. Estrone sulfate is an important marker of estrogenicity in women. Fertil Steril 2001;in press
15. Kuhnz W, Blode H, Zimmermann H. Pharmacokinetics of exogenous and natural estrogens and antiestrogens. In Oettel M, Schillinger E, eds. Estrogens and Antiestrogens. Berlin: Springer-Verlag, 1999;2:262-322
16. Mandel FP, Geola FL, Lu JKH. Biologic effects of various doses of ethinyl estradiol in postmenopausal women. Obstet Gynecol 1982;59:673-9
17. Mandel FP, Geola FL, Meldrum DR. Biological effects of various doses of vaginally administered conjugated equine estrogens in postmenopausal women. J Clin Endocrinol Metab 1983;57:133-9
18. Maschak CA, Lobo RA, Dozono-Takano R, et al. Comparison of pharmacokinetic properties of various estrogen formulations. Am J Obstet Gynecol 1982;144:511-18